Conference Proceedings

Timing of Androgen Deprivation Therapy for Prostate Cancer Patients after Radiation: Planned Combined Analysis of Two Randomized Phase 3 Trials

DA Loblaw, J Bassett, C D'Este, G Pond, P Cheung, M Frydenberg, MT King, H Lukka, S Malone, JL Millar, RL Milne, T Pickles, R Smith, MR Stockler, S Turner, KH Tai, H Woo, G Duchesne

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | ELSEVIER SCIENCE INC | Published : 2018

Grants

Funding Acknowledgements

D.A. Loblaw: Consultant; Glaxo Smith Kline, Merck, Bristol-Myers Squibb, Novartis, Roche, Astellas, Janssen Oncology, AbbVie, Bayer, Ferring. Travel Expenses; Janssen Oncology, Astellas. Patent/License Fees/Copyright; Sunnybrook Research Institute. Oversees the running of the charity; Prostate Cure Foundation. J. Bassett: None. C. D'Este: None. G. Pond: Employee; Roche. P. Cheung: Independent Contractor; Ontario Ministry of Health and Long-Term Care. Research Grant; Sanofi Aventis, Pfizer, Abbvie. M. Frydenberg: None. M.T. King: Research Grant; AbbVie, Bristol-Myers Squibb. H. Lukka: None. S. Malone: None. J. L. Millar: Stock; Resmed, Estia Health. R. L. Milne: None. T. Pickles: Honoraria; AbbVie, Ferring, Bayer, Sanofi. Consultant; AbbVie. R. Smith: None. M.R. Stockler: None. S. Turner: None. K. Tai: None. H. Woo: Consultant; Janssen Oncology. Speaker's Bureau; Astellas, Ipsen. G. Duchesne: Research Grant; Tolmar. Honoraria; Tolmar.